S&P 500

5.277,51

0,80%

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Nuvalent Inc (NUVL)
Nuvalent Inc (NUVL) Notícias

NUVL

Nuvalent (NUVL)

Nuvalent Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:NUVL

1 2 3 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
29/05/2024	17:43	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NUVL	Nuvalent Inc
29/05/2024	07:30	PR Newswire (US)	Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference	NASDAQ:NUVL	Nuvalent Inc
16/05/2024	17:10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NUVL	Nuvalent Inc
16/05/2024	17:01	PR Newswire (US)	Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655	NASDAQ:NUVL	Nuvalent Inc
09/05/2024	07:46	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:NUVL	Nuvalent Inc
09/05/2024	07:30	PR Newswire (US)	Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results	NASDAQ:NUVL	Nuvalent Inc
08/04/2024	17:30	PR Newswire (US)	Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024	NASDAQ:NUVL	Nuvalent Inc
05/03/2024	18:52	PR Newswire (US)	Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024	NASDAQ:NUVL	Nuvalent Inc
27/02/2024	09:00	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:NUVL	Nuvalent Inc
27/02/2024	08:42	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:NUVL	Nuvalent Inc
27/02/2024	08:30	PR Newswire (US)	Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:NUVL	Nuvalent Inc
27/02/2024	08:15	PR Newswire (US)	Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520	NASDAQ:NUVL	Nuvalent Inc
12/02/2024	08:30	PR Newswire (US)	Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors	NASDAQ:NUVL	Nuvalent Inc
01/02/2024	08:30	PR Newswire (US)	Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	NASDAQ:NUVL	Nuvalent Inc
08/01/2024	08:30	PR Newswire (US)	Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated Milestones	NASDAQ:NUVL	Nuvalent Inc
26/12/2023	18:31	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NUVL	Nuvalent Inc
21/12/2023	08:30	PR Newswire (US)	Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:NUVL	Nuvalent Inc
14/11/2023	08:30	PR Newswire (US)	Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results	NASDAQ:NUVL	Nuvalent Inc
01/11/2023	07:30	PR Newswire (US)	Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day	NASDAQ:NUVL	Nuvalent Inc
17/10/2023	17:05	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:NUVL	Nuvalent Inc
16/10/2023	22:55	PR Newswire (US)	Nuvalent Announces Pricing of Public Offering of Common Stock	NASDAQ:NUVL	Nuvalent Inc
16/10/2023	08:30	PR Newswire (US)	Nuvalent Announces Public Offering of Common Stock	NASDAQ:NUVL	Nuvalent Inc
13/10/2023	07:30	PR Newswire (US)	Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC	NASDAQ:NUVL	Nuvalent Inc
04/10/2023	13:21	PR Newswire (US)	Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety Profile	NASDAQ:NUVL	Nuvalent Inc
18/09/2023	07:30	PR Newswire (US)	Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium	NASDAQ:NUVL	Nuvalent Inc
05/09/2023	07:30	PR Newswire (US)	Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors	NASDAQ:NUVL	Nuvalent Inc
31/08/2023	07:30	PR Newswire (US)	Nuvalent to Participate in Upcoming September Investor Conferences	NASDAQ:NUVL	Nuvalent Inc
10/08/2023	07:30	PR Newswire (US)	Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results	NASDAQ:NUVL	Nuvalent Inc
01/08/2023	07:30	PR Newswire (US)	Nuvalent to Participate in Upcoming August Investor Conferences	NASDAQ:NUVL	Nuvalent Inc
20/06/2023	17:46	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:NUVL	Nuvalent Inc